Endo International plc (ENDPQ)
| Previous close | 0.0006 |
| Open | 0.0003 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0003 - 0.0006 |
| 52-week range | 0.0001 - 0.0800 |
| Volume | |
| Avg. volume | 117,747 |
| Market cap | 141,132 |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.4100 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePar Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product solution.
- PR Newswire
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
- PR Newswire
Endo Announces Confirmation of Plan of Reorganization
Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the "Plan"), clearing the path for the Company to successfully complete its financial restructuring. Under the Plan, substantially all of the Company's assets are being sold to a new entity, Endo, Inc., over 95% of which is owned by holders of the Company's first lien debt. The transaction
